Is eNAMPT/visfatin a potential serum marker of papillary thyroid cancer?
nicotinamide phosphoribosyltransferase
papillary thyroid cancer
recurrence
serum marker
visfatin
Journal
Therapeutic advances in endocrinology and metabolism
ISSN: 2042-0188
Titre abrégé: Ther Adv Endocrinol Metab
Pays: United States
ID NLM: 101532143
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
08
2021
accepted:
04
03
2022
entrez:
22
4
2022
pubmed:
23
4
2022
medline:
23
4
2022
Statut:
epublish
Résumé
The role of nicotinamide phosphoribosyltransferase (NAMPT)/visfatin in a more aggressive course of many malignancies has been proven. Previous studies have noticed the importance of visfatin in thyroid neoplastic tissue, but the diagnostic and prognostic value of its serum concentration has not been investigated so far. Our study aimed to consider whether extracellular NAMPT (eNAMPT) could be a potential serum marker in recurrent papillary thyroid cancer (PTC). It was a prospective observational study with consecutive enrolment. We recruited 100 patients with PTC after thyroidectomy with postoperative The visfatin serum concentrations in patients diagnosed with PTC and in healthy subjects were not statistically significantly different ( We have not found visfatin as a potential serum marker of papillary thyroid cancer. Also, eNAMPT has no prognostic value in assessing the risk of disease recurrence or metastasis in PTC management.
Identifiants
pubmed: 35450096
doi: 10.1177/20420188221090005
pii: 10.1177_20420188221090005
pmc: PMC9016592
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20420188221090005Informations de copyright
© The Author(s), 2022.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Références
Endokrynol Pol. 2020;71(4):299-305
pubmed: 32901910
Endocrine. 2016 Aug;53(2):497-504
pubmed: 26767650
Thyroid. 2016 Mar;26(3):347-55
pubmed: 26700485
Ann Nutr Metab. 2017;70(4):338-345
pubmed: 28618407
Ann Transl Med. 2019 Dec;7(23):785
pubmed: 32042801
Anticancer Res. 2013 Aug;33(8):3047-52
pubmed: 23898059
Endokrynol Pol. 2018;69(1):34-74
pubmed: 29442352
Endocr Connect. 2021 Apr 26;10(4):462-470
pubmed: 33764900
Science. 2005 Jan 21;307(5708):426-30
pubmed: 15604363
Eur J Endocrinol. 1996 Feb;134(2):168-73
pubmed: 8630514
Tumour Biol. 2015 Sep;36(10):7859-63
pubmed: 25946974
Int J Endocrinol. 2016;2016:7402469
pubmed: 26884761
Br J Pharmacol. 2016 Jul;173(14):2182-94
pubmed: 27128025
Mol Cell Biol. 1994 Feb;14(2):1431-7
pubmed: 8289818
Horm Metab Res. 2018 Sep;50(9):653-660
pubmed: 30184561
Thyroid. 2019 Aug;29(8):1044-1051
pubmed: 31088334
Biomed Res Int. 2018 Feb 06;2018:1316390
pubmed: 29546048
Eur J Pharmacol. 2019 Dec 15;865:172738
pubmed: 31614144
Croat Med J. 2014 Oct;55(5):507-13
pubmed: 25358883
BMC Endocr Disord. 2019 Jun 7;19(1):58
pubmed: 31174521
Metabolism. 2018 May;82:72-87
pubmed: 29330025
Biomed Res Int. 2018 Jan 4;2018:8576179
pubmed: 29516012
Cancer Biol Ther. 2010 Jul 15;10(2):119-25
pubmed: 20647743
Maturitas. 2012 Mar;71(3):301-8
pubmed: 22261365
Anticancer Res. 2016 Feb;36(2):503-7
pubmed: 26851003
Clin Cancer Res. 2018 Mar 1;24(5):1202-1215
pubmed: 29203587
CA Cancer J Clin. 2018 Jan;68(1):55-63
pubmed: 29092098
Oncol Lett. 2018 May;15(5):6648-6654
pubmed: 29725408
Int J Cancer. 2019 Jan 1;144(1):136-149
pubmed: 30121947